IP Library Granted Patent US 9,637,456
Granted Patent B2
US 9,637,456 · App. 14/770,499 · Granted May 2, 2017

2,3-disubstituted 1-acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors

Inventors: Dominique Amans (Brentford, GB); Stephen John Atkinson (Stevenage, GB); Lee Andrew Harrison (Stevenage, GB); David Jonathan Hirst (Stevenage, GB); Robert Peter Law (Stevenage, GB); Matthew Lindon (Stevenage, GB); Alexander Preston (Stevenage, GB); Jonathan Thomas Seal (Stevenage, GB); Christopher Roland Wellaway (Stevenage, GB)
Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
C07D215/44A61K31/4375A61K31/4706A61K31/4709A61K31/496A61K31/497A61K31/506A61K31/5377A61K31/5386C07D215/227C07D215/46C07D215/48C07D401/04C07D401/12C07D401/14C07D405/04C07D405/14C07D409/12C07D409/14C07D413/04C07D413/12C07D413/14C07D417/12C07D417/14C07D471/04C07D471/08C07D487/08C07D498/04C07D498/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,637,456
App. No.
14/770,499
Granted
May 2, 2017
Kind
B2
Abstract

The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.

Claims (6)

1. A compound which is (2S,3R,4R)-1-acetyl-2-cyclopropyl-3-methyl-4-((4-methylpyrimidin-2-yl)amino)-1,2,3,4-tetrahydroquinoline-6-carboxamide, represented by the formula:

or a salt thereof.

2. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

3. A pharmaceutical composition which comprises the compound or a pharmaceutically acceptable salt thereof according to claim 2 and one or more pharmaceutically acceptable carriers, diluents or excipients.

4. The compound according to claim 1 in the form of a free base.

5. A pharmaceutical composition which comprises the compound according to claim 4 and one or more pharmaceutically acceptable carriers, diluents or excipients.

Assignments (2)
CHANGE OF ADDRESS Recorded Apr 16, 2025
From: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
Reel/Frame 070854/0469 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2015
From: AMANS, DOMINIQUE; ATKINSON, STEPHEN JOHN; HARRISON, LEE ANDREW; HIRST, DAVID JONATHAN; LAW, ROBERT PETER; LINDON, MATTHEW J.; PRESTON, ALEXANDER G.; SEAL, JONATHAN THOMAS; WELLAWAY, CHRISTOPHER ROLAND
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
Reel/Frame 036517/0615 →
Continuity (3)
Provisional Application 61781583 · Mar 14, 2013
Provisional Application 61882798 · Sep 26, 2013
Related Publication 20160016908A1 · Jan 21, 2016